A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active:	Yes
Cancer Type:	Head and Neck Cancer	NCT ID:	NCT04974398
Trial Phases:	Phase III	Protocol IDs:	AK105-304 (primary) NCI-2022-08325
Eligibility:	12 - 75 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Akeso
NCI Full Details:	http://clinicaltrials.gov/show/NCT04974398

Summary

This study is a randomized, double-blind, multi-center phase III clinical study to compare
the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with
chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.